Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

DermBiont axed trials of its original lead dermatology gel, the biotech confirmed to Endpoints News, and with little investor appetite for microbiome-based therapies, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Scoop: With in­vestor in­ter­est dried up in mi­cro­bio­me ther­a­pies, DermBiont piv­ots to oth­er top­i­cals and nears close of Se­ries B

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B